CD4 and neoplasm: While CD8+T cells are typically favored for targeting tumors, evidence suggests that after DCs phagocytose apoptotic tumor cells, the antigens can still be presented on MHC class II molecules, thereby activating tumor-specific CD4+ T cell responses (101).